Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Radicava (edaravone) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Drug (Brand / Generic)

Radicava™ / edaravone

Developer

Mitsubishi Tanabe Pharma America

Therapy Class

Nootropic and neuroprotective agent

Current Indication

Amyotrophic lateral sclerosis (ALS)

Market Sector

Central nervous system (CNS)

Development Status

Approved in the US, Japan, and South Korea
Expand

Go Top